#AsteraLabs领涨芯片股 Astera Labs surges 16.39%! Hits new highs! UBS: CXL market upgrade and MRVL, ALAB forecasts revised up!
UBS believes the CXL opportunity is evolving from a single CPU memory expander to XPU attach, rack-wide coherent fabric, and even multi-rack fabric. As Agentic AI drives growth in CPU and XPU device counts, there is upside potential for both CXL attach rate and per-processor value. The CXL market is expected to approach $70-10B by 2030, with the value of high-speed I/O and coherent interconnects being revised upward.
On June 29, UBS analyst Timothy Arcuri and his team published a research report, significantly raising financial expectations and price targets for Marvell Technology (MRVL) and Astera Labs (ALAB). The core logic is that the Compute Express Link (CXL) technology market is entering an inflection point.
UBS believes that CXL, as a cache-coherent, low-latency, high-bandwidth interconnect technology built on PCIe, is gradually becoming a key enabling technology for data centers, with its market space continuously expanding.
Analyst Arcuri further noted that the ultimate TAM of the CXL market remains uncertain, mainly due to differences in attach rates and solution configurations (including varied deployment methods for expanders and switches). However, he believes that the CXL attach value per XPU/CPU will continue to rise from the current ~$100-200 to higher multiples. By 2030, total shipments of XPUs, head node CPUs, and standalone CPUs are expected to reach approximately 73 million units.
Notably, UBS has distinctly different rating stances on the two companies — MRVL is rated "Buy" while ALAB is only rated "Neutral," even though the target price raise for ALAB (+95%) is much larger than that for MRVL (+48%). This contrast is key to understanding UBS's core logic.
Analysis of Astera Labs (ALAB)
1. Currently small business scale: Astera Labs' Leo CXL Extender product currently generates annual revenue of approximately $25 million, with Microsoft (MSFT) as a key customer.
2. Growth catalysts
UBS expects two catalysts to drive ALAB's CXL business growth:
Increased procurement from Microsoft: Expected to enter volume phase in the second half of 2026; New customer introduction: In 2027, will benefit from a design win from a new US hyperscale cloud service provider.
Why "Neutral"? Although the upward revision in ALAB's EPS forecast (+49.8% for 2028) is even larger than MRVL's (+11.9%), UBS maintains a "Neutral" rating.
This reflects:
Scale gap: ALAB's 2028 revenue estimate of $3.3 billion is only one-seventh of MRVL's $23.9 billion.
Competitive landscape: UBS explicitly points out that Marvell currently holds a leading market share in CXL products, but as the market expands, Astera Labs and Broadcom will become more important players — meaning ALAB's market position is that of a "follower" rather than a "leader."
Valuation already high: ALAB's stock price has risen over 142% year-to-date, currently around $391.74, and the target price of $400 implies only about 2% upside, reflecting UBS's judgment that the current valuation is fully priced in.
UBS believes the CXL opportunity is evolving from a single CPU memory expander to XPU attach, rack-wide coherent fabric, and even multi-rack fabric. As Agentic AI drives growth in CPU and XPU device counts, there is upside potential for both CXL attach rate and per-processor value. The CXL market is expected to approach $70-10B by 2030, with the value of high-speed I/O and coherent interconnects being revised upward.
On June 29, UBS analyst Timothy Arcuri and his team published a research report, significantly raising financial expectations and price targets for Marvell Technology (MRVL) and Astera Labs (ALAB). The core logic is that the Compute Express Link (CXL) technology market is entering an inflection point.
UBS believes that CXL, as a cache-coherent, low-latency, high-bandwidth interconnect technology built on PCIe, is gradually becoming a key enabling technology for data centers, with its market space continuously expanding.
Analyst Arcuri further noted that the ultimate TAM of the CXL market remains uncertain, mainly due to differences in attach rates and solution configurations (including varied deployment methods for expanders and switches). However, he believes that the CXL attach value per XPU/CPU will continue to rise from the current ~$100-200 to higher multiples. By 2030, total shipments of XPUs, head node CPUs, and standalone CPUs are expected to reach approximately 73 million units.
Notably, UBS has distinctly different rating stances on the two companies — MRVL is rated "Buy" while ALAB is only rated "Neutral," even though the target price raise for ALAB (+95%) is much larger than that for MRVL (+48%). This contrast is key to understanding UBS's core logic.
Analysis of Astera Labs (ALAB)
1. Currently small business scale: Astera Labs' Leo CXL Extender product currently generates annual revenue of approximately $25 million, with Microsoft (MSFT) as a key customer.
2. Growth catalysts
UBS expects two catalysts to drive ALAB's CXL business growth:
Increased procurement from Microsoft: Expected to enter volume phase in the second half of 2026; New customer introduction: In 2027, will benefit from a design win from a new US hyperscale cloud service provider.
Why "Neutral"? Although the upward revision in ALAB's EPS forecast (+49.8% for 2028) is even larger than MRVL's (+11.9%), UBS maintains a "Neutral" rating.
This reflects:
Scale gap: ALAB's 2028 revenue estimate of $3.3 billion is only one-seventh of MRVL's $23.9 billion.
Competitive landscape: UBS explicitly points out that Marvell currently holds a leading market share in CXL products, but as the market expands, Astera Labs and Broadcom will become more important players — meaning ALAB's market position is that of a "follower" rather than a "leader."
Valuation already high: ALAB's stock price has risen over 142% year-to-date, currently around $391.74, and the target price of $400 implies only about 2% upside, reflecting UBS's judgment that the current valuation is fully priced in.
